Seattle genetics inc /wa (SGEN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10
Operating activities:
Net loss

-168,402

25,830

-91,913

-79,238

-13,329

-119,805

-67,446

76,273

-111,715

-59,201

50,021

-56,360

-59,990

-55,138

-31,752

-32,743

-20,478

-24,856

-26,438

-47,502

-21,690

-26,684

-15,566

-17,590

-16,301

-15,671

-23,686

-6,899

-16,264

-10,596

-13,652

-17,236

-12,298

-27,165

-40,685

-51,506

-32,674

-34,546

-34,856

-8,323

11,460

Adjustments to reconcile net loss to net cash used by operating activities
Share-based compensation

33,617

47,553

27,875

26,157

25,715

25,732

20,813

15,517

16,838

15,901

15,906

17,528

14,465

15,426

12,760

12,103

12,182

13,116

11,148

9,837

7,735

11,601

10,279

9,435

9,304

9,789

8,231

6,780

6,606

7,431

6,272

5,536

6,101

5,964

5,490

4,262

4,268

4,232

3,736

3,178

3,184

Depreciation and amortization

5,967

9,628

4,241

3,819

6,086

8,371

4,339

6,458

6,864

7,876

6,178

5,431

4,784

4,764

4,624

4,416

4,230

3,745

3,725

3,612

3,423

3,382

3,209

3,062

2,837

2,558

2,216

2,114

1,727

1,597

1,539

1,529

1,494

1,391

1,008

896

875

938

934

874

816

Amortization of right-of-use assets

2,526

-

-

-

2,421

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premiums, accretion of discounts, and (gains) losses on debt securities

511

-

-

-

1,142

-

-

-

-

156

-688

1,871

-1,836

-428

-571

-1,404

-2,343

-1,837

-373

-328

-308

815

-141

-192

-332

-353

-297

-459

-774

-804

-754

-569

-447

-9,268

-1,081

-1,298

-827

-481

-600

-950

-1,398

(Gains) losses on equity securities

-59,079

60,382

-5,690

-42,693

38,125

-55,546

-23,765

67,822

18,825

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-114

-

-396

-235

-224

-194

-356

-177

-194

-105

-293

-141

-195

-197

-152

-153

-104

891

-94

-375

294

1,727

288

214

18

57

42

71

28

Unrealized losses on equity securities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities
Interest receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

617

42

196

-373

-178

-36

446

-270

-107

-1,233

1,042

Accounts receivable, net

-11,388

45,683

8,054

25,309

10,674

-6,239

2,544

31,397

17,531

-5,658

18,492

-1,747

11,759

-3,193

7,379

5,350

-538

-10,568

18,248

-4,337

10,339

-4,569

8,912

-2,991

8,388

300

-18,461

2,948

11,278

-1,713

3,603

-25,028

1,626

39,508

4,436

2,390

-10,658

4,017

82

1,365

-66,307

Inventories

-1,192

-6,102

18,884

5,914

13,997

-21,933

4,239

-982

11,937

-859

-8,410

8,524

-7,401

-3,521

-30

11,625

3,087

12,448

-2,974

4,420

-382

5,910

7,050

1,447

1,971

1,069

-12,657

4,929

-4,015

3,451

8,599

9,944

6,284

6,041

3,428

0

0

-

-

-

-

Prepaid expenses and other assets

8,207

955

2,861

1,127

-7,402

18,750

-9,175

-6,537

11,529

86

-3,435

5,964

-445

159

3,412

-1,865

2,672

4,897

-3,506

4,213

-3,652

4,031

94

453

654

636

-468

-1,291

2,940

675

-1,930

1,306

1,500

-1,505

962

1,690

427

-1,195

-6

-4,081

1,226

Lease liability

3,341

2,027

1,678

471

2,484

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

-29

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

17,286

7,466

-18,544

21,572

1,856

8,150

-1,639

7,172

-9,763

6,012

3,118

8,394

6,668

3,907

-521

4,176

3,870

3,812

-10,365

13,605

-9,629

11,589

-12,483

14,761

4,451

8,443

-390

-1,197

6,076

5,980

-4,572

Deferred revenue

0

-7,028

-9,974

-9,908

-6,690

-8,899

-7,735

-8,929

-8,350

-6,737

-3,961

-4,112

-2,068

-8,634

-8,491

-10,476

-9,030

-12,999

-7,480

-14,371

-13,526

-11,184

-173

-4,139

-7,685

7,923

6,892

-6,945

-2,043

38,024

965

-2,076

-1,804

633

-5,100

5,186

7,718

10,629

12,915

-11,937

-31,807

Other liabilities

-2,367

15,642

32,488

11,731

-12,410

31,570

12,756

19,060

-28,629

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used by operating activities

-69,059

-11,851

-60,646

-34,013

-57,227

-24,285

-11,116

-20,971

-147,164

-2,394

-8,231

-44,731

-63,544

-15,054

-31,589

-32,491

-17,837

-18,956

-40,559

-46,557

-27,131

-20,783

-11,791

-4,183

-23,242

6,253

29,927

-7,418

-29,872

50,198

-24,734

13,272

-27,855

-37,092

-42,115

-35,251

-9,573

-21,958

-10,552

-5,257

44,575

Investing activities:
Purchases of securities

124,922

326,856

518,565

69,074

78,481

137,978

131,677

180,051

62,628

67,357

191,782

45,507

208,370

160,439

114,180

216,417

112,736

577,599

55,527

58,191

63,346

120,195

97,629

105,243

128,207

142,739

130,312

139,042

71,089

158,672

91,131

131,622

123,641

95,316

60,454

84,720

238,899

124,676

118,879

63,937

146,107

Proceeds from maturities of securities

152,000

411,000

155,000

92,500

127,500

128,001

60,699

90,000

120,022

115,000

125,500

230,000

182,700

150,300

80,000

320,000

149,500

87,000

103,300

90,800

86,100

152,900

118,500

105,200

127,500

86,500

186,200

137,300

70,700

107,300

96,000

117,000

104,851

107,006

141,043

133,300

117,610

143,275

99,890

98,700

101,391

Proceeds from sales of securities

19,996

0

0

0

0

0

14,869

77,014

48,469

0

0

0

60,056

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-1

5,000

0

5,825

0

0

0

0

-

-

-

-

Purchases of property and equipment

25,256

18,990

18,432

20,797

12,534

6,278

5,451

4,817

4,673

-13,893

5,059

22,973

14,583

8,950

8,201

3,351

7,333

4,366

4,069

2,586

2,371

7,395

2,641

3,999

3,141

7,361

6,402

2,137

6,254

5,806

2,353

1,271

1,055

6,236

3,431

1,281

304

415

876

1,204

1,053

Acquisition of Cascadian Therapeutics, Inc., net of cash acquired

-

-

-

-

-

0

0

0

598,151

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

21,818

65,154

-381,997

2,629

36,485

-16,255

-61,560

-17,854

-496,961

19,879

-71,341

161,520

19,803

-19,089

-42,381

100,232

29,431

-494,965

43,704

55,028

20,383

26,282

18,230

-4,042

-3,848

-63,411

49,297

-3,879

-6,643

-57,179

7,516

-15,893

-14,020

5,452

71,599

47,096

-121,593

18,434

-17,768

33,559

-45,769

Financing activities:
Net proceeds from issuance of common stock

-

-

-

-

-

0

0

77

658,165

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-65

168,118

0

0

0

0

Proceeds from exercise of stock options and employee stock purchase plan

21,786

27,793

23,306

11,226

26,826

3,269

28,846

11,145

11,905

15,320

10,608

4,548

10,835

11,787

12,911

4,800

5,698

2,102

5,298

7,971

12,392

1,260

4,898

2,244

7,786

1,745

12,673

3,995

16,786

6,713

11,389

10,038

7,584

7,169

2,824

6,548

3,390

1,880

1,598

2,859

1,040

Net cash provided by financing activities

21,786

27,793

571,997

11,226

26,826

3,269

28,846

11,222

670,070

15,320

10,608

4,548

10,835

11,787

12,911

4,800

5,698

2,102

531,916

7,971

12,392

1,260

4,898

2,244

7,786

1,745

12,673

3,995

16,786

6,713

11,389

10,038

7,584

7,169

2,824

6,483

171,508

1,880

1,598

2,859

1,040

Effect of exchange rate changes on cash and cash equivalents

9

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-25,446

81,096

129,354

-20,158

6,084

-37,271

-43,830

-27,603

25,945

32,805

-68,964

121,337

-32,906

-22,356

-61,059

72,541

17,292

-511,819

535,061

16,442

5,644

6,759

11,337

-5,981

-19,304

-55,413

91,897

-7,302

-19,729

-268

-5,829

7,417

-34,291

-24,471

32,308

18,328

40,342

-1,644

-26,722

31,161

-154